VCP and amyotrophic lateral sclerosis: Our work links two distinct ALS-causal genes, highlights impaired protein degradation as an underlying disease mechanism, and raises the possibility that boosting the expression of VCP may be a promising therapeutic target in mutSOD1 patients with ALS.